000			01751cam a2200241 4500500
005			20260322004716.0
041			_afre
042			_adc
100	1	0	_aCaillé, Sarah _eauthor
700	1	0	_aBrixi, Hedia _eauthor
700	1	0	_aPerrier, Marine _eauthor
700	1	0	_ade Mestier, Louis _eauthor
700	1	0	_aLe Collen, Lauriane _eauthor
700	1	0	_aDeguelte, Sophie _eauthor
700	1	0	_aDelemer, Brigitte _eauthor
700	1	0	_aCadiot, Guillaume _eauthor
245	0	0	_aDuodenopancreatic involvement in MEN1
260			_c2022.
500			_a14
520			_aMultiple endocrine neoplasia type 1 (MEN1) is a rare, hereditary, autosomal dominant disease. It is characterized by the presence of cell hyperplasia or tumors of the endocrine system: parathyroid, duodenopancreatic, thymic, and bronchial neuroendocrine tumors (NETs), and pituitary and adrenal adenomas. Duodenopancreatic involvement is common and accounts for 60% of the causes of death from MEN1. Duodenopancreatic NETs can be functional or non-functional, benign or malignant. The most common functional duodenopancreatic NETs are gastrinomas and insulinomas. Patients with MEN1 require multidisciplinary management (gastroenterologist, endocrinologist, pathologist, radiologist, nuclear physician, surgeon) in an expert center and lifelong follow-up. Failure to diagnose MEN1 is a missed opportunity for patients and their families. This review focuses on duodenopancreatic NETs in MEN1, specifically their diagnostic and therapeutic management.
786	0		_nHépato-Gastro & Oncologie Digestive | 29 | 1 | 2022-01-01 | p. 12-23 | 2115-3310
856	4	1	_uhttps://stm.cairn.info/journal-hepato-gastro-oncologie-digestive-2022-1-page-12?lang=en&redirect-ssocas=7080
999			_c1742368 _d1742368